Seoul Pharma Co. Ltd
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms o… Read more
Seoul Pharma Co. Ltd (018680) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.064x
Based on the latest financial reports, Seoul Pharma Co. Ltd (018680) has a cash flow conversion efficiency ratio of -0.064x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.66 Billion) by net assets (₩41.30 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Seoul Pharma Co. Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Seoul Pharma Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Seoul Pharma Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seoul Pharma Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Concejo AB (publ)
ST:CNCJO-B
|
0.058x |
|
KEKROPS H.T.B. INH EO-30
F:KE1
|
N/A |
|
Censof Holdings Bhd
KLSE:5195
|
0.051x |
|
MONOLITHIC POWER (NQG.SG)
STU:NQG
|
0.099x |
|
Property Perfect Public Company Limited
BK:PF
|
0.009x |
|
Fancamp Exploration Ltd.
PINK:FNCJF
|
-0.018x |
|
Paterson Resources Ltd
AU:PSL
|
0.000x |
|
Movano Inc
NASDAQ:MOVE
|
0.946x |
Annual Cash Flow Conversion Efficiency for Seoul Pharma Co. Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Seoul Pharma Co. Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩40.17 Billion | ₩-3.01 Billion | -0.075x | -154.86% |
| 2023-12-31 | ₩38.56 Billion | ₩5.26 Billion | 0.137x | +6282.46% |
| 2022-12-31 | ₩35.42 Billion | ₩-78.21 Million | -0.002x | +97.50% |
| 2021-12-31 | ₩18.96 Billion | ₩-1.67 Billion | -0.088x | -144.43% |
| 2020-12-31 | ₩28.85 Billion | ₩5.74 Billion | 0.199x | +93.15% |
| 2019-12-31 | ₩28.45 Billion | ₩2.93 Billion | 0.103x | +522.01% |
| 2018-12-31 | ₩50.31 Billion | ₩-1.23 Billion | -0.024x | -15.51% |
| 2017-12-31 | ₩53.86 Billion | ₩-1.14 Billion | -0.021x | +53.00% |
| 2016-12-31 | ₩42.07 Billion | ₩-1.89 Billion | -0.045x | -205.98% |
| 2015-12-31 | ₩33.53 Billion | ₩1.42 Billion | 0.042x | -10.82% |
| 2014-12-31 | ₩31.10 Billion | ₩1.48 Billion | 0.048x | +460.77% |
| 2013-12-31 | ₩32.25 Billion | ₩-425.00 Million | -0.013x | -103.63% |
| 2012-12-31 | ₩25.38 Billion | ₩9.22 Billion | 0.363x | -- |